AEON Biopharma Gains FDA Support and Slashes Debt Over 90% With $6M PIPE
AEON Biopharma’s FDA Type 2a meeting endorsed its analytical similarity strategy for ABP-450 under the 351(k) pathway, guiding completion of its analytical comparability package in 2026. The company cut its debt by over 90% through a $6 million PIPE financing and convertible note exchange and holds $6.2 million in cash.
1. FDA Endorses Analytical Plan for ABP-450
The FDA reviewed AEON’s initial analytical comparability results for ABP-450 and deemed the proposed similarity strategy reasonable under the 351(k) biosimilar pathway. AEON plans to complete the bulk of its analytical comparability program in 2026 and intends to request a Type 2b meeting to define remaining requirements.
2. $6M PIPE Financing and 90% Debt Reduction
AEON closed a $6 million private investment in public equity financing and exchanged Daewoong-held convertible notes, reducing outstanding debt by more than 90%. The company reported $6.2 million in cash as of March 31, plus $0.9 million from an April ATM offering, funding operations into the third quarter of 2026.
3. New CFO Appointment and Upcoming Milestones
John Bencich was named Chief Financial Officer, bringing over 25 years of experience in corporate strategy and capital markets. AEON will present structural comparability data at the American Headache Society meeting June 4–7 and targets a Type 2b FDA interaction in the second half of 2026.